Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372718 | 0.82 | GAA (0.34) | GAAMAPT | |
| SCHEMBL20919991 | 0.80 | GAA (0.38) | GAAMAPT | |
| SCHEMBL7159138 | 0.77 | MAPT (0.45) | GAAMAPT | |
| SCHEMBL2531037 | 0.69 | KDM4E (0.30) | — | |
| SCHEMBL29789697 | 0.66 | MAPT (0.50) | GAAMAPT | |
| SCHEMBL2255782 | 0.66 | MAPT (0.50) | GAAMAPT | |
| SCHEMBL9293762 | 0.64 | GAA (0.43) | GAAMAPT | |
| SCHEMBL4587067 | 0.63 | GAA (0.42) | GAAMAPT | |
| SCHEMBL4389562 | 0.63 | GAA (0.42) | GAAMAPT | |
| SCHEMBL9281528 | 0.63 | GAA (0.42) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088785-B2 | Therapeutic compound and treatments | MEDISYN TECHNOLOGIES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100137253-A1 | THERAPEUTIC COMPOUND AND TREATMENTS | MEDISYN TECHNOLOGIES, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7652029-B2 | Therapeutic compound and treatments | MEDISYN TECHNOLOGIES, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1778228-A2 | THERAPEUTIC COMPOUND AND TREATMENTS | Medisyn Technologies, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006010127-A2 | THERAPEUTIC COMPOUND AND TREATMENTS | MEDISYN TECHNOLOGIES, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060014770-A1 | Inhibiting cell growth including cancer such as leukemia, melanoma, cancer of non-small cell lung, colon , CNS, ovarian , renal , prostate , breast , and pancreas | COUSINEAU, HENRY | 2006-01-19 | — | — | US | disclosed |
| JP-2005220067-A | PEST-CONTROLLING AGENT | SUMITOMO CHEMICAL CO LTD | 2005-08-18 | — | — | JP | disclosed |
| US-20030176314-A1 | Compounds for the treatment of pain | H. LUNDBECK A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | disclosed |
| EP-0398904-A1 | PHOTOCHEMICAL MARKING OF SUBSTRATES | TRAQSON LIMITED (GB) | 1990-11-28 | — | — | EP | disclosed |
| WO-1989005994-A1 | PHOTOCHEMICAL MARKING OF SUBSTRATES | TRAQSON LIMITED (GB) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | NPFFR2, NPFFR1, OPRL1 | GAA 3614/4885MAPT 2186/4885 |
| US-20060014770-A1 | Inhibiting cell growth including cancer such as leukemia, melanoma, cancer of non-small cell lung, colon , CNS, ovarian , renal , prostate , breast , and pancreas | MCL1, MRPL37, BRDT | GAA 1131/4885MAPT 1743/4885 |
| US-20100137253-A1 | THERAPEUTIC COMPOUND AND TREATMENTS | MDH1, MDH2, MBOAT7 | GAA 106/4885MAPT 199/4885 |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | NPFFR1, NPFFR2, SSTR3 | GAA 3802/4885MAPT 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.